Jim Cramer Says “Bristol Myers has a Faint Pulse”

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 25 stocks Jim Cramer recently shared insights on. While discussing drug stocks, Cramer mentioned BMY and said:

“Of course, some of the rally’s nothing more than the left-behind stocks playing catch up. The drug stocks had a rare day in the sun. I wish I had something good to say about them. Maybe it’s enough to say that Bristol Myers has a faint pulse, one that lasted until the end of the session.”

Jim Cramer Says "Bristol Myers has a Faint Pulse"

A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution.

Bristol-Myers Squibb (NYSE:BMY) develops and markets biopharmaceutical products across areas like oncology, immunology, cardiovascular, and neuroscience. The company provides a diverse portfolio of therapies for cancer, autoimmune diseases, and chronic conditions. During an early June episode, Cramer showed disappointment in the company stock, as he said:

“Bristol Myers, Charitable Trust owns it. So far, we’re not happy with COBENFY. It’s a little disappointing. We need to see that stock back up at 60.”

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.